ng28ÄϹ¬½«ÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏչʾLeqembi? (lecanemab-irmb) III ÆÚÁÙ´²Ñо¿µÄ×îÐÂÊý¾Ý¼°ÆäËü°¢¶û´Äº£Ä¬²¡¹ÜÏßÑо¿½á¹û

LEQEMBI ƤÏÂ×¢Éä¼ÁÐ͵Ä×îÐÂÑо¿½øÕ¹

 

ng28ÄϹ¬Öêʽ»áÉçÐû²¼£¬½«ÔÚµÚ16½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©Äê»áÉÏÐû²¼Æä°¢¶û´Äº£Ä¬²¡£¨AD£©ÖÎÁÆÒ©ÎïLEQEMBI?£¨lecanemab-irmb£©100 mg/mLµÄIIIÆÚClarity ADÑо¿µÄ×îÐÂÊý¾ÝÒÔ¼°ÕýÔÚ¿ª·¢µÄƤÏÂÖƼÁµÄÐÂÊý¾Ý£¬¸Ã¼¯»á½«ÓÚ2023Äê10ÔÂ24ÈÕÖÁ27ÈÕÔÚÃÀ¹úÂíÈøÖîÈûÖݲ¨Ê¿¶Ù¾ÙÐС £¼¯»áÉÏ£¬³ýÁ˽éÉÜng28ÄϹ¬LEQEMBIµÄÊý¾ÝÍ⣬»¹½«½éÉÜE2511£¨Ò»ÖÖÑо¿ÐÔÔ­¼¡ÇòÂÑ°×ÊÜÌ弤øA£¨TrkA£©ÑôÐԱ乹µ÷Àí¼Á£¨PAM£©£©µÄIÆÚÊý¾ÝÒÔ¼°¹«Ë¾AD²úÆ·ÏßµÄÆäËüÑо¿¡£Ôڴ˴μ¯»áÉÏ£¬ng28ÄϹ¬½«Í¨¹ýÎ峡¿ÚÍ·±¨¸æºÍÊ®³¡º£±¨Õ¹Ê¾À´½éÉÜÊý¾ÝºÍÑо¿½á¹û¡£BioArctic ½«¾Í lecanemab ×÷¿ÚÍ·±¨¸æ¡£

×îÐÂרÌâÑÐÌÖ»á4¡ª¡ªLecanemabÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡£ººã¾ÃÁÆЧ¡¢Ô¤²âÐÔÉúÎï±ê¼ÇÎïºÍÐÂÐÍƤϸøÒ©

  • ÔÚÃÀ¹ú¶«²¿Ê±¼ä10ÔÂ25ÈÕ17:25-18:05¾ÙÐеÄÒ»´ÎÍ»ÆÆÐÔÑÐÌÖ»áÉÏ£¬ng28ÄϹ¬½«Õ¹Ê¾Clarity AD¿ÉÑ¡tau PET×ÝÏò×ÓÑо¿µÄ×îÐÂÊý¾Ý¡£¸ÃÑÝʾ½«°üÀ¨¶ÔµÍºÍÖеÈ+¸ßtauÑÇ×éµÄʺóÆÊÎö£¬µÍtauÑÇ×é´ú±í¼²²¡µÄÔçÆڽ׶Σ¬ÌرðÊÇÔÚIIIÆÚ½¹µãÑо¿ºÍ¿ª·Å±êÇ©À©Õ¹Ñо¿ÖнøÐÐÑо¿¡£±ðµÄ£¬»¹½«½éÉÜÑо¿Æ¤ÏÂÖƼÁµÄ×îÐÂÇé¿ö£¬°üÀ¨ÖÐÆÚÄþ¾²ÐԺ͵í·ÛÑùÂÑ°× PET ¶Ô´óÄÔÖеí·ÛÑùÂÑ°×µÄÓ°Ïì¡£
  • Christopher van Dyckҽѧ²©Ê¿¡¢Keith Johnsonҽѧ²©Ê¿ºÍReisa Sperlingҽѧ²©Ê¿½«ÔÚng28ÄϹ¬Michael Irizarryҽѧ²©Ê¿£¨¹«¹²ÎÀÉú˶ʿ£©Ö÷³ÖµÄС×éÌÖÂÛÖÐÌÖÂÛÕâЩ·¢Ã÷¡£
  • ±¾´ÎÑÐÌÖ»áµÄÍøÂçÖ±²¥¿ÉÔÚng28ÄϹ¬Öêʽ»áÉçÍøÕ¾ÉÏԢĿ¡£

ng28ÄϹ¬Éñ¾­ÄÚ¿ÆÁÙ´²Ñо¿¸ß¼¶¸±×ܲá¢ÁÙ´²Ö¤¾ÝÉú³É²¿¸±Ê×ϯÁÙ´²¹ÙMichael Irizarryҽѧ²©Ê¿ÌåÏÖ£¬”°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øÐÔµÄÍç¹Ì¼²²¡£¬ÐèÒªÔçÆÚÕï¶ÏºÍÁ¬ÐøÖÎÁÆ¡£LEQEMBIÄܹ»Çå³ý¸ß¶¾ÐÔÔ­ÏËά£¬´Ó¶øÖ§³Ö°¢¶û´Äº£Ä¬²¡µÄÉñ¾­Ôª¹¦Ð§£¬¶ø¸ß¶¾ÐÔÔ­ÏËάÔÚ°ß¿é±»Çå³ýºóÈÔ»á¼ÌÐøµ¼ÖÂÉñ¾­ÔªËðÉ˺ÍËÀÍö¡£ÎÒÃÇÆÚ´ýÔÚ2023ÄêCTADÉÏ·ÖÏíеÄLEQEMBIµÍtauÑÇ×éÊý¾ÝºÍƤÏÂ×¢ÉäÊý¾Ý¡£”

ÆäËüÖ÷Òª¿ÚÍ·±¨¸æ°üÀ¨

  • Lecanemab£ºlecanemabºÍdonanemabÓë²î±ðµí·ÛÑùÂÑ°×-¦ÂµÄ½áºÏ¸Å¿ö£¨OC19£¬ÓÉBioArctic¹«Ë¾½éÉÜ£©¡£
  • ÐÂÐÍTrkAµ÷Àí¼ÁE2511ÔÚ IÆÚÁÙ´²Ñо¿ÖÐÓëÖÐÊàÉñ¾­ÏµÍ³µ¨¼îÄܰеã½áºÏ£¨OC34£©¡£
  • ÐÂÐÍCSF tauÉúÎï±ê¼ÇÎï¿ÉÓÃÓÚÉ¢·¢ÐÔ°¢¶û´Äº£Ä¬²¡µÄ¼²²¡·ÖÆÚ£¨OC2£©¡£

ng28ÄϹ¬Ñݽ²ÁбíÈçÏÂ:

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

±¾ÐÂΟåÌÖÂÛÁËÒ©ÎïÔÚ¿ª·¢ÖÐÑо¿ÐÔÓÃ;£¬²¢·Çת´ï¹ØÓÚÁÆЧºÍÄþ¾²ÐԵĽáÂÛ£¬²»°ü¹ÜÈκÎÑо¿ÐÔÒ©ÎｫÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃÒ©Æ·¼à¹Ü»ú¹¹Åú×¼¡£

 

MEDIA CONTACTS:
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@Eisai.com

Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net